These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 22281156)

  • 1. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
    Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
    Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and experimental therapeutic studies of the calcium channel blocker bepridil: detection of viable Leishmania (L.) chagasi by real-time PCR.
    Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
    Exp Parasitol; 2011 Jun; 128(2):111-5. PubMed ID: 21354141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine.
    Tempone AG; Perez D; Rath S; Vilarinho AL; Mortara RA; de Andrade HF
    J Antimicrob Chemother; 2004 Jul; 54(1):60-8. PubMed ID: 15163652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
    Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
    J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.
    da Costa-Silva TA; Galisteo AJ; Lindoso JA; Barbosa LR; Tempone AG
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis.
    Tempone AG; Mortara RA; de Andrade HF; Reimão JQ
    Int J Antimicrob Agents; 2010 Aug; 36(2):159-63. PubMed ID: 20554161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo evaluation using phosphatidylserine-liposomes.
    Pinto EG; da Costa-Silva TA; Tempone AG
    Acta Trop; 2014 Sep; 137():206-10. PubMed ID: 24905294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
    Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L
    J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis.
    Smith L; Serrano DR; Mauger M; Bolás-Fernández F; Dea-Ayuela MA; Lalatsa A
    Mol Pharm; 2018 Jul; 15(7):2570-2583. PubMed ID: 29762040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting intracellular Leishmania (L.) infantum with nitazoxanide entrapped into phosphatidylserine-nanoliposomes: An experimental study.
    Pinto EG; Barbosa LRS; Mortara RA; Tempone AG
    Chem Biol Interact; 2020 Dec; 332():109296. PubMed ID: 33096056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of allicin on promastigotes and intracellular amastigotes of Leishmania donovani and L. infantum.
    Jesús Corral-Caridad M; Moreno I; Toraño A; Domínguez M; Alunda JM
    Exp Parasitol; 2012 Dec; 132(4):475-82. PubMed ID: 22995646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
    Garnier T; Mäntylä A; Järvinen T; Lawrence J; Brown M; Croft S
    J Antimicrob Chemother; 2007 Oct; 60(4):802-10. PubMed ID: 17715126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic or therapeutic administration of Agaricus blazei Murill is effective in treatment of murine visceral leishmaniasis.
    Valadares DG; Duarte MC; Ramírez L; Chávez-Fumagalli MA; Martins VT; Costa LE; Lage PS; Ribeiro TG; Castilho RO; Fernandes AP; Régis WC; Soto M; Tavares CA; Coelho EA
    Exp Parasitol; 2012 Oct; 132(2):228-36. PubMed ID: 22824583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.
    Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd
    Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective effects of Euterpe oleracea (açai) on Leishmania (Leishmania) amazonensis and Leishmania infantum.
    Da Silva BJM; Souza-Monteiro JR; Rogez H; Crespo-López ME; Do Nascimento JLM; Silva EO
    Biomed Pharmacother; 2018 Jan; 97():1613-1621. PubMed ID: 29793323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro.
    Freitas EO; Nico D; Guan R; Meyer-Fernandes JR; Clinch K; Evans GB; Tyler PC; Schramm VL; Palatnik-de-Sousa CB
    PLoS One; 2015; 10(4):e0124183. PubMed ID: 25909893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections.
    Carvalheiro M; Esteves MA; Santos-Mateus D; Lopes RM; Rodrigues MA; Eleutério CV; Scoulica E; Santos-Gomes G; Cruz ME
    Eur J Pharm Biopharm; 2015 Jun; 93():346-52. PubMed ID: 25936854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
    Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.